OMCL - Omnicell, Inc.
NASDAQ
->
Healthcare
->
Health Information Services
Mountain View,
United States
Type: Equity
OMCL price evolution
OMCL
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $556.78 | $512.36 | $467.97 | |
| Short term investments | ||||
| Net receivables | $251.76 | $241.13 | $248.51 | $252.03 |
| Inventory | $95.06 | $93.26 | $103.47 | $110.1 |
| Total current assets | $1011.26 | $995.67 | $989.92 | $927.57 |
| Long term investments | $50.3 | $43.91 | $42.95 | |
| Property, plant & equipment | $137.06 | $137.42 | $135.56 | $133.59 |
| Goodwill & intangible assets | $934.78 | $940.47 | $946.98 | |
| Total noncurrent assets | $1295.99 | $1293.84 | $1299.31 | |
| Total investments | $50.3 | $43.91 | $42.95 | |
| Total assets | $2303.59 | $2291.66 | $2283.76 | $2226.88 |
| Current liabilities | ||||
| Accounts payable | $47.81 | $49.75 | $43.15 | $45.03 |
| Deferred revenue | $218.25 | $229.78 | $180.36 | |
| Short long term debt | ||||
| Total current liabilities | $961.52 | $407.12 | $416.36 | $367.79 |
| Long term debt | $604.96 | $605.01 | $569.66 | |
| Total noncurrent liabilities | $681.73 | $678.79 | $670.13 | |
| Total debt | $604.96 | $605.01 | $603.57 | |
| Total liabilities | $1072.26 | $1088.85 | $1095.16 | $1037.92 |
| Shareholders' equity | ||||
| Retained earnings | $367.05 | $358.42 | $354.68 | $370.36 |
| Other shareholder equity | $1231.33 | -$14.88 | -$14.83 | $1188.95 |
| Total shareholder equity | $1202.81 | $1188.6 | $1188.95 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $467.97 | $330.36 | $349.05 | $485.93 |
| Short term investments | ||||
| Net receivables | $252.03 | $299.47 | $240.89 | $190.12 |
| Inventory | $110.1 | $147.55 | $119.92 | $96.3 |
| Total current assets | $927.57 | $881.81 | $780.7 | $829.41 |
| Long term investments | $42.95 | $32.92 | $18.39 | $22.16 |
| Property, plant & equipment | $133.59 | $132.01 | $119.69 | $114.19 |
| Goodwill & intangible assets | $946.98 | $977.18 | $1016.52 | $667.52 |
| Total noncurrent assets | $1299.31 | $1328.95 | $1361.79 | $995.09 |
| Total investments | $42.95 | $32.92 | $18.39 | $22.16 |
| Total assets | $2226.88 | $2210.76 | $2142.5 | $1824.5 |
| Current liabilities | ||||
| Accounts payable | $45.03 | $63.39 | $71.51 | $40.31 |
| Deferred revenue | $180.36 | $156.33 | $132.39 | $105.73 |
| Short long term debt | $488.15 | |||
| Total current liabilities | $367.79 | $428.45 | $876.16 | $276.42 |
| Long term debt | $569.66 | $566.57 | $39.91 | $516.1 |
| Total noncurrent liabilities | $670.13 | $652.17 | $119.65 | $580.58 |
| Total debt | $603.57 | $605.98 | $528.06 | $516.1 |
| Total liabilities | $1037.92 | $1080.62 | $995.81 | $857 |
| Shareholders' equity | ||||
| Retained earnings | $370.36 | $390.73 | $368.57 | $290.72 |
| Other shareholder equity | $1188.95 | -$17.09 | -$8.41 | -$5.52 |
| Total shareholder equity | $1188.95 | $1130.14 | $1146.69 | $967.5 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $276.79 | $246.15 | $258.85 | |
| Cost of revenue | $162.44 | $153.53 | ||
| Gross Profit | $114.35 | $92.62 | $105.4 | |
| Operating activities | ||||
| Research & development | $21.1 | $22.06 | ||
| Selling, general & administrative | $90.03 | $92.41 | ||
| Total operating expenses | $111.13 | $114.47 | $128.77 | |
| Operating income | $3.22 | -$21.85 | ||
| Income from continuing operations | ||||
| EBIT | $3.22 | -$21.85 | ||
| Income tax expense | $4.46 | -$2.15 | -$4.14 | |
| Interest expense | -$4.97 | -$4.02 | $4.85 | |
| Net income | ||||
| Net income | $3.73 | -$15.68 | -$14.38 | |
| Income (for common shares) | $3.73 | -$15.68 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1147.11 | $1295.95 | $892.21 | |
| Cost of revenue | $706.96 | $478.92 | ||
| Gross Profit | $496.84 | $588.99 | $413.29 | |
| Operating activities | ||||
| Research & development | $104.97 | $70.16 | ||
| Selling, general & administrative | $486.34 | $307.61 | ||
| Total operating expenses | $531.71 | $591.31 | $377.77 | |
| Operating income | -$2.32 | $35.53 | ||
| Income from continuing operations | ||||
| EBIT | -$2.32 | $35.53 | ||
| Income tax expense | $0.26 | -$8.1 | -$2.85 | |
| Interest expense | $14.76 | $0.13 | $6.18 | |
| Net income | ||||
| Net income | -$20.37 | $5.65 | $32.19 | |
| Income (for common shares) | $5.65 | $32.19 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | $3.73 | -$15.68 | ||
| Operating activities | ||||
| Depreciation | $22.81 | $23.18 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.03 | $8.64 | ||
| Total cash flows from operations | $58.7 | $49.95 | ||
| Investing activities | ||||
| Capital expenditures | -$13.55 | -$12.34 | ||
| Investments | ||||
| Total cash flows from investing | -$39.23 | -$13.55 | -$12.34 | -$55.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.1 | $8.04 | ||
| Net borrowings | ||||
| Total cash flows from financing | -$1.15 | -$16.63 | $11.93 | $23.42 |
| Effect of exchange rate | $0.88 | -$0.25 | -$0.56 | -$1.35 |
| Change in cash and equivalents | $91.91 | $28.28 | $48.98 | $148.14 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5.65 | $77.85 | $32.19 | |
| Operating activities | ||||
| Depreciation | $99.17 | $84.93 | $71.59 | |
| Business acquisitions & disposals | $2.07 | -$354.16 | -$225 | |
| Stock-based compensation | $68.25 | $53.16 | $44.7 | |
| Total cash flows from operations | $77.78 | $231.81 | $185.87 | |
| Investing activities | ||||
| Capital expenditures | -$60.74 | -$58.34 | -$54.87 | |
| Investments | ||||
| Total cash flows from investing | -$55.02 | -$58.67 | -$412.5 | -$279.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$12.03 | $67.35 | $52.52 | |
| Net borrowings | $408.49 | |||
| Total cash flows from financing | $23.42 | -$20.95 | $47.36 | $456.27 |
| Effect of exchange rate | -$1.35 | -$0.94 | -$0.97 | $0.44 |
| Change in cash and equivalents | $148.14 | -$2.79 | -$134.3 | $362.71 |
News
|
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
Zacks · via Yahoo Finance
17 Feb 2025
|
|
Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises
Zacks · via Yahoo Finance
10 Feb 2025
|
|
Omnicell (OMCL) Reports Next Week: Wall Street Expects Earnings Growth
Zacks · via Yahoo Finance
30 Jan 2025
|
|
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues
Zacks · via Yahoo Finance
10 Jan 2025
|
|
MYGN Stock Gains Following Collaboration With Hannah Storm
Zacks · via Yahoo Finance
10 Jan 2025
|
|
Expanding Global Network, Vaccine Sales Support PAHC Stock
Zacks · via Yahoo Finance
9 Jan 2025
|
|
BSX Stock Rises Following Bolt Medical Acquisition Deal Announcement
Zacks
8 Jan 2025
|
|
Reasons to Add Penumbra Stock to Your Portfolio Now
Zacks · via Yahoo Finance
7 Jan 2025
|
|
Why Omnicell (OMCL) Might be Well Poised for a Surge
Zacks · via Yahoo Finance
18 Dec 2024
|
|
Omnicell Introduces OmniSphere Platform, Stock to Gain
Zacks · via Yahoo Finance
12 Dec 2024
|
Fundamentals
| Market cap | $1.50B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 45.99M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.87 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.05 |
| Quick ratio | 0.95 |